Hide filtersShow filters × Close Bryan, Garnier & Co acts as Sole Financial Advisor to clinical-stage biologics company BiosanaPharma on its global strategic partnership with Alvotech Bryan, Garnier & Co acts as Sole Financial Advisor to Wandercraft on its $45 million Fundraising Bryan, Garnier & Co acted as Sole Financial Advisor to the shareholders of CMN on its partnership with MBO & Co Bryan, Garnier & Co acts as Joint Global Coordinator and Joint Bookrunner to Nicox on its EUR 15 million Follow-on Offering of shares and warrants Bryan, Garnier & Co acts as Lead Joint Bookrunner to leading German Specialty Pharmaceuticals provider Medios AG on its EUR 93 million Follow-on Offering Bryan, Garnier & Co acts as Joint Bookrunner on Valneva’s Nasdaq & Euronext Paris USD 102m Follow-on Offering Bryan, Garnier & Co acts as Sole Financial Advisor to XVIVO on its acquisition of STAR Teams, and as Joint Global Coordinator on subsequent SEK 250 million Follow-on Offering Bryan, Garnier & Co acts as Sole Financial Advisor to Cleerly on its USD 43 million Series B Fundraising Bryan, Garnier & Co acts as Joint Bookrunner on BICO’s SEK 2 billion Follow-on Offering Bryan, Garnier & Co acts as Sole Financial Advisor to the shareholders of CanPharma GmbH on the sale of the company to Health House International Ltd (ASX:HHI) Bryan, Garnier & Co acts as Sole Global Coordinator and Sole Bookrunner on Heidelberg Pharma’s EUR 20 million Follow-on Offering Bryan, Garnier & Co acts as Sole Financial Advisor to FCDE on its acquisition of a majority stake in Didactic alongside its management team
